CareerExamPro

BPS Board Certified Pain Management Pharmacist (BCPMP) practice test

8 practice questions for this exam, each with a full explanation and cited rule or blueprint reference.

Start practising

ROCN, CMC/CSC, C-OBE, BCPMP & NRCME: practice drill

10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.

Exam Snapshot & Official Blueprint

Official Exam Fee
$600 (Board of Pharmacy Specialties — Pearson VUE 2026)
Format & Time Limit
150 MCQs · 3 hours 45 minutes (immediate preliminary score in 2026)
Passing Standard
Scaled score 500 out of 800
Typical Prep Incumbents
$400–$800+ (ASHP/ACCP — newer BPS pain specialty)

Official Domain Breakdown

Exam DomainWeight
Opioid Pharmacology, Equianalgesic Rotation & Cross-Tolerance Math34%
Multimodal, Neuropathic & Non-Opioid Pain Pharmacotherapy34%
Opioid Risk Mitigation, OIC (PAMORAs), Naloxone & Regulatory Practice32%

High-Yield Formulas, Statutes & Rules Cheat Sheet

Frequently Asked Questions

What changed for BPS pharmacy specialty exams in 2026?

BPS transitioned exam delivery to Pearson VUE in January 2026 with continuous testing and immediate preliminary score reporting.

Practice tests that prepare you for this exam

Practise by topic

About this exam

Agency / Issuer
BPS
Region
United States

Exact question counts, passing scores, and allowed reference materials vary by testing window and state/agency. Always confirm current rules with the official testing provider.

Sample questions

A 72-year-old man with painful diabetic peripheral neuropathy, benign prostatic hyperplasia, orthostatic hypotension, and Stage 4 chronic kidney disease (estimated CrCl 24 mL/min) requires first-line oral pharmacotherapy for burning neuropathic foot pain. Which regimen is most appropriate?

  1. Initiate renally adjusted low-dose gabapentin (100 to 300 mg orally once daily at bedtime) with slow titration and sedation monitoring.
  2. Initiate duloxetine 60 mg orally once daily because SNRIs undergo exclusively hepatic elimination and require no renal function restrictions.
  3. Initiate amitriptyline 50 mg orally at bedtime because tertiary-amine TCAs have minimal anticholinergic and orthostatic risks in older adults.
  4. Initiate standard-dose gabapentin 300 mg orally three times daily advancing to 1,800 mg/day by day 4 because renal clearance does not affect gabapentin.
Show the answer

A. Initiate renally adjusted low-dose gabapentin (100 to 300 mg orally once daily at bedtime) with slow titration and sedation monitoring.

First-line oral classes for painful diabetic neuropathy include gabapentinoids, SNRIs (duloxetine, venlafaxine), and TCAs, but comorbidities dictate selection: FDA labeling advises avoiding duloxetine when CrCl <30 mL/min due to metabolite accumulation; tertiary-amine TCAs (amitriptyline) are Beer Criteria high-risk drugs in older adults and worsen BPH urinary retention and orthostasis; and gabapentin is excreted ~100% unchanged renally, so standard TID dosing at CrCl 24 mL/min causes severe somnolence, myoclonus, and encephalopathy. Renally adjusted low-dose gabapentin (e.g., 100–300 mg once daily, max ~300–700 mg/day for CrCl 15–29 mL/min) is the safest choice.

Reference: AAN Painful Diabetic Neuropathy Guideline / FDA Gabapentin & Duloxetine Prescribing Information / AGS Beers Criteria

A 65-year-old patient taking scheduled oral oxycodone for chronic cancer pain reports hard, infrequent stools (one bowel movement every 5 days with straining, Bowel Function Index score 68) despite daily scheduled polyethylene glycol and senna. Physical examination and abdominal imaging exclude mechanical gastrointestinal obstruction. What is the most evidence-based next pharmacologic step?

  1. Discontinue senna and polyethylene glycol and switch to docusate sodium 100 mg twice daily plus psyllium husk fiber monotherapy.
  2. Reassure the patient and wait 4 additional weeks without changing therapy because complete physiologic tolerance to opioid-induced constipation develops rapidly.
  3. Administer oral naltrexone 50 mg daily to block enteric mu-opioid receptors while preserving full central nervous system opioid analgesia.
  4. Initiate a peripherally acting mu-opioid receptor antagonist (PAMORA) such as naloxegol, naldemedine, or subcutaneous methylnaltrexone.
Show the answer

D. Initiate a peripherally acting mu-opioid receptor antagonist (PAMORA) such as naloxegol, naldemedine, or subcutaneous methylnaltrexone.

Patients do not develop tolerance to opioid-induced constipation (OIC). Per AGA and NCCN guidelines, docusate alone is ineffective for OIC and bulk-forming fiber (psyllium) can worsen impaction. When OIC persists despite scheduled osmotic and stimulant laxatives—and mechanical GI obstruction has been ruled out—the recommended step is a PAMORA (naloxegol, naldemedine, or methylnaltrexone), which selectively blocks peripheral enteric mu-opioid receptors without crossing the blood-brain barrier to reverse CNS analgesia (unlike systemic naltrexone, which precipitates acute withdrawal and loss of analgesia).

Reference: AGA Clinical Practice Guideline on the Medical Management of Opioid-Induced Constipation / BPS BCPMP Blueprint

A 54-year-old patient with chronic lumbar radiculopathy has been stable for 4 years on oral oxycodone 15 mg every 6 hours (90 MME/day) and clonazepam 0.5 mg twice daily prescribed by psychiatry for panic disorder. Applying the CDC Clinical Practice Guideline for Prescribing Opioids (2022–2026), which clinical action best reflects current evidence-based standards?

  1. Abruptly discontinue oxycodone today to comply with a mandatory federal 50 MME/day ceiling, because rapid cessation carries minimal risk of withdrawal or self-harm.
  2. Offer naloxone with overdose education, optimize multimodal nonopioid analgesia, and coordinate gradual risk reduction rather than abrupt cessation.
  3. Convert the patient directly to an extended-release opioid at 120 MME/day to eliminate breakthrough peaks and discontinue naloxone because he is opioid-tolerant.
  4. Refuse to offer naloxone unless the patient has a prior emergency department visit for illicit heroin overdose, as prescription opioids rarely cause respiratory depression.
Show the answer

B. Offer naloxone with overdose education, optimize multimodal nonopioid analgesia, and coordinate gradual risk reduction rather than abrupt cessation.

The CDC Clinical Practice Guideline for Prescribing Opioids (2022, current through 2026) explicitly advises against abrupt opioid discontinuation or inflexible forced tapering in physically dependent patients due to severe risks of acute withdrawal, unmanaged pain, suicidal ideation, and transition to illicit opioids. Instead, clinicians should optimize multimodal nonopioid therapies, coordinate with behavioral health on benzodiazepine-opioid co-prescribing risks, and proactively offer naloxone whenever overdose risk factors exist—including dosages >=50 MME/day or concurrent benzodiazepine use.

Reference: CDC Clinical Practice Guideline for Prescribing Opioids for Pain (MMWR 2022; active 2026 standard) / BPS BCPMP

Taking this exam soon?

Tell us which exam domains or calculation drills you want more practice on.

Other 2026 New Clinical & DOT Boards exams